Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions
Sign Up to like & getrecommendations! Published in 2018 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-018-4594-2
Abstract: IntroductionHigh-dose melphalan (HDMel) is the most common conditioning chemotherapy regimen for autologous stem cell transplantation (SCT) in patients affected by multiple myeloma (MM). No consensus exists for the emetogenicity or prophylaxis of chemotherapy-induced nausea and… read more here.
Keywords: chemotherapy; cell transplantation; dose melphalan; stem cell ... See more keywords
High‐dose melphalan‐based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.15137
Abstract: Considering the unsatisfactory results of salvage therapies for patients with relapsed/refractory acute myeloid leukaemia (R/R‐AML), their value before allogeneic haematopoietic stem cell transplantation (HSCT) remains questionable. However, direct allogeneic HSCT following established conditioning regimens applied… read more here.
Keywords: conditioning; high dose; dose melphalan; transplantation ... See more keywords
The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16764
Abstract: Recent advances in multiple myeloma include numerous approvals of novel therapies with unprecedented efficacy, a rapid and sustained tempo of new drug development, and further refinements to prognostication to include minimal residual disease (MRD) testing… read more here.
Keywords: high dose; multiple myeloma; dose melphalan; melphalan autologous ... See more keywords
Comparable peri‐transplant mortality and incidence of febrile neutropenia after high‐dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient
Sign Up to like & getrecommendations! Published in 2025 at "British Journal of Haematology"
DOI: 10.1111/bjh.70104
Abstract: is the increased use of unmodified high-dose melphalan conditioning, which could lead to higher gut flora translocation into the bloodstream. Gastrointestinal involvement in AL patients did not appear to predict higher GI toxicity, as the… read more here.
Keywords: transplant; renal function; cell; dose melphalan ... See more keywords
Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-03-838672
Abstract: TO THE EDITOR: In patients with complex medical conditions, determining the etiology of thrombocytopenia can be challenging. This is particularly true in patients undergoing treatment with high-dose melphalan and autologous stem cell transplantation (HDM/SCT). Virtually… read more here.
Keywords: high dose; cell transplantation; dose melphalan; stem cell ... See more keywords
Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-204278
Abstract: Background: Melphalan, 200mg/m2, is recommended by the National Comprehensive Cancer Network (NCCN) guideline as the standard conditioning regimen for autologous stem cell transplantation (ASCT) in young newly diagnosed multiple myeloma (NDMM) patients. Reduced-dose melphalan is… read more here.
Keywords: conditioning regimen; selinexor; melphalan; dose melphalan ... See more keywords
The impact of pulmonary function in patients undergoing autologous stem cell transplantation.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2021004863
Abstract: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is an established therapy for patients with hematological malignancies. The age of patients undergoing auto-HSCT, and therefore the co-morbidities, has increased during the last decades.… read more here.
Keywords: high dose; dose melphalan; auto hsct; patients undergoing ... See more keywords